Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A. Shah NP, et al. Among authors: lambert a. Haematologica. 2010 Feb;95(2):232-40. doi: 10.3324/haematol.2009.011452. Haematologica. 2010. PMID: 20139391 Free PMC article. Clinical Trial.
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Hochhaus A, Müller MC, Radich J, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim DW, Lipton JH, Bleickardt E, Lambert A, Hughes TP. Hochhaus A, et al. Among authors: lambert a. Leukemia. 2009 Sep;23(9):1628-33. doi: 10.1038/leu.2009.156. Epub 2009 Jul 30. Leukemia. 2009. PMID: 19641527
First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy.
Hamdy FC, Lamb AD, Tullis IDC, Verrill C, Rombach I, Rao SR, Colling R, Barber PR, Volpi D, Barbera-Martin L, Lopez JF, Omer A, Hewitt A, Lovell S, Niederer J, Lambert A, Snoeck J, Thomson C, Leslie T, Bryant RJ, Mascioni A, Jia F, Torgov M, Wilson I, Gudas J, Wu AM, Olafsen T, Vojnovic B. Hamdy FC, et al. Among authors: lambert a. Eur J Nucl Med Mol Imaging. 2024 Jun 10. doi: 10.1007/s00259-024-06713-x. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 38853153
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study.
Van Laethem JL, Borbath I, Prenen H, Geboes KP, Lambert A, Mitry E, Cassier PA, Blanc JF, Pilla L, Batlle JF, Garrote MR, Pazo-Cid RA, Gallego I, Smith KE, Ellmark P, Pico de Coaña Y, Ambarkhane SV, Macarulla T. Van Laethem JL, et al. Among authors: lambert a. Lancet Oncol. 2024 May 31:S1470-2045(24)00263-8. doi: 10.1016/S1470-2045(24)00263-8. Online ahead of print. Lancet Oncol. 2024. PMID: 38834087
Outcomes of heart transplants in children with heterotaxy syndrome.
Alsoufi B, Kozik D, Lambert AN, Deshpande S, Sparks JD, Trivedi J. Alsoufi B, et al. Among authors: lambert an. Eur J Cardiothorac Surg. 2024 Jun 3;65(6):ezae204. doi: 10.1093/ejcts/ezae204. Eur J Cardiothorac Surg. 2024. PMID: 38788682
1,446 results